A detailed history of Pro Share Advisors LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 26,667 shares of PCVX stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,667
Previous 21,607 23.42%
Holding current value
$2.07 Million
Previous $1.36 Million 34.29%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$59.79 - $81.05 $302,537 - $410,113
5,060 Added 23.42%
26,667 $1.82 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $148,974 - $208,301
3,285 Added 17.93%
21,607 $1.36 Million
Q3 2023

Nov 13, 2023

BUY
$46.0 - $53.1 $13,892 - $16,036
302 Added 1.68%
18,322 $934,000
Q2 2023

Aug 10, 2023

BUY
$34.66 - $54.07 $139,679 - $217,902
4,030 Added 28.81%
18,020 $899,000
Q1 2023

May 11, 2023

SELL
$36.27 - $47.2 $64,197 - $83,544
-1,770 Reduced 11.23%
13,990 $524,000
Q4 2022

Feb 02, 2023

BUY
$20.58 - $47.95 $99,463 - $231,742
4,833 Added 44.23%
15,760 $755,000
Q3 2022

Nov 04, 2022

BUY
$21.69 - $28.53 $10,064 - $13,237
464 Added 4.43%
10,927 $262,000
Q2 2022

Aug 01, 2022

SELL
$17.68 - $26.58 $59,475 - $89,415
-3,364 Reduced 24.33%
10,463 $228,000
Q1 2022

May 10, 2022

SELL
$17.46 - $26.36 $42,392 - $64,002
-2,428 Reduced 14.94%
13,827 $334,000
Q4 2021

Feb 08, 2022

SELL
$19.32 - $26.45 $1,391 - $1,904
-72 Reduced 0.44%
16,255 $387,000
Q3 2021

Nov 12, 2021

SELL
$20.26 - $26.97 $65,176 - $86,762
-3,217 Reduced 16.46%
16,327 $414,000
Q2 2021

Aug 13, 2021

BUY
$16.45 - $24.06 $78,137 - $114,285
4,750 Added 32.11%
19,544 $440,000
Q1 2021

May 14, 2021

BUY
$18.66 - $29.16 $54,058 - $84,476
2,897 Added 24.35%
14,794 $292,000
Q4 2020

Feb 09, 2021

BUY
$26.57 - $51.74 $316,103 - $615,550
11,897 New
11,897 $316,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.61B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.